# Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region

> **NCT03082976** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 108 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03082976
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-16
- **Primary completion:** 2019-07-24
- **Final completion:** 2019-07-24
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082976, "Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03082976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*